Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
Standard
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. / Sobh, M; Michallet, M; Gahrton, G; Iacobelli, S; van Biezen, A; Schönland, S; Petersen, E; Schaap, N; Bonifazi, F; Volin, L; Meijer, E; Niederwieser, D; El Cheikh, J; Tabrizi, R; Fegeux, N; Finke, J; Bunjes, D; Cornelissen, J; Einsele, H; Bruno, B; Potter, M; Fanin, R; Mohty, M; Garderet, L; Kröger, N.
In: LEUKEMIA, Vol. 30, No. 10, 10.2016, p. 2047-2054.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
AU - Sobh, M
AU - Michallet, M
AU - Gahrton, G
AU - Iacobelli, S
AU - van Biezen, A
AU - Schönland, S
AU - Petersen, E
AU - Schaap, N
AU - Bonifazi, F
AU - Volin, L
AU - Meijer, E
AU - Niederwieser, D
AU - El Cheikh, J
AU - Tabrizi, R
AU - Fegeux, N
AU - Finke, J
AU - Bunjes, D
AU - Cornelissen, J
AU - Einsele, H
AU - Bruno, B
AU - Potter, M
AU - Fanin, R
AU - Mohty, M
AU - Garderet, L
AU - Kröger, N
PY - 2016/10
Y1 - 2016/10
N2 - We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.
AB - We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.
KW - Adolescent
KW - Adult
KW - Aged
KW - Europe
KW - Female
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Male
KW - Middle Aged
KW - Multiple Myeloma
KW - Survival Rate
KW - Transplantation, Homologous
KW - Treatment Outcome
KW - Young Adult
KW - Journal Article
U2 - 10.1038/leu.2016.101
DO - 10.1038/leu.2016.101
M3 - SCORING: Journal article
C2 - 27118410
VL - 30
SP - 2047
EP - 2054
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 10
ER -